clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Ureteral Obstruction D014517 10 associated lipids
Rodent Diseases D012376 4 associated lipids
Osteomyelitis D010019 10 associated lipids
Pancreatitis D010195 10 associated lipids
Skin Ulcer D012883 6 associated lipids
Cysts D003560 4 associated lipids
Urination Disorders D014555 9 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Abnormalities, Drug-Induced D000014 10 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
FDA approves Biaxin for MAC prophylaxis. Food and Drug Administration. 1995 J Int Assoc Physicians AIDS Care pmid:11363096
van der Meer JT and Danner SA Clarithromycin therapy for Mycobacterium avium complex bacteremia. 1995 Ann. Intern. Med. pmid:7778831
Burette A and Glupczynski Y Helicobacter pylori: the place of the new macrolides in the eradication of the bacteria in peptic ulcer disease. 1995 Infection pmid:7782116
Savarino V et al. Helicobacter pylori eradication and reinfection. 1995 Lancet pmid:7783564
Comley JC and Sterling AM Effect of atovaquone and atovaquone drug combinations on prophylaxis of Pneumocystis carinii pneumonia in SCID mice. 1995 Antimicrob. Agents Chemother. pmid:7785975
Odenholt-Tornqvist I et al. Postantibiotic effects and postantibiotic sub-MIC effects of roxithromycin, clarithromycin, and azithromycin on respiratory tract pathogens. 1995 Antimicrob. Agents Chemother. pmid:7695310
Struillou L et al. Activities of roxithromycin against Mycobacterium avium infections in human macrophages and C57BL/6 mice. 1995 Antimicrob. Agents Chemother. pmid:7785988
Fong IW et al. Clarithromycin versus cefaclor in lower respiratory tract infections. The Canadian Bronchitis Study Group. 1995 Clin Invest Med pmid:7788958
Goddard A and Logan R One-week low-dose triple therapy: new standards for Helicobacter pylori treatment. 1995 Eur J Gastroenterol Hepatol pmid:7866804
Weits J and Sprenger HG [Surgical treatment of lymphadenitis caused by non-tuberculous mycobacteria in children]. 1995 Ned Tijdschr Geneeskd pmid:8524431
Ramírez Ramos A [Treatment of Helicobacter pylori infection: current status]. 1995 Rev Gastroenterol Peru pmid:8520021
Lee D et al. Localized Mycobacterium avium-intracellulare mastitis in an immunocompetent woman with silicone breast implants. 1995 Plast. Reconstr. Surg. pmid:7809228
Adamek RJ et al. [Short-term triple therapy with pantoprazole, clarithromycin and metronidazole for the healing of Helicobacter pylori infection]. 1995 Dtsch. Med. Wochenschr. pmid:7889816
Midoneck SR and Etingin OR Clarithromycin-related toxic effects of digoxin. 1995 N. Engl. J. Med. pmid:7477159
Forslund T et al. Disseminated cutaneous infection due to Mycobacterium chelonae in a patient with rheumatoid arthritis, amyloidosis, and renal failure. 1995 Nephrol. Dial. Transplant. pmid:7478131
Cavalieri SJ et al. Synergistic activities of clarithromycin and antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis. 1995 Antimicrob. Agents Chemother. pmid:7492101
Matsiota-Bernard P et al. Mycobacterium genavense infection in a patient with AIDS who was successfully treated with clarithromycin. 1995 Clin. Infect. Dis. pmid:7548515
Citron DM et al. Activity of ampicillin/sulbactam, ticarcillin/clavulanate, clarithromycin, and eleven other antimicrobial agents against anaerobic bacteria isolated from infections in children. 1995 Clin. Infect. Dis. pmid:7548597
Ishii K et al. A new pharmacokinetic model including in vivo dissolution and gastrointestinal transit parameters. 1995 Biol. Pharm. Bull. pmid:7550125
Harris AW et al. Eradication of Helicobacter pylori with lansoprazole and clarithromycin. 1995 Aliment. Pharmacol. Ther. pmid:7605863
Katelaris PH et al. A randomized prospective comparison of clarithromycin versus amoxycillin in combination with omeprazole for eradication of Helicobacter pylori. 1995 Aliment. Pharmacol. Ther. pmid:7605864
Yousfi MM et al. Metronidazole, omeprazole and clarithromycin: an effective combination therapy for Helicobacter pylori infection. 1995 Aliment. Pharmacol. Ther. pmid:7605865
Chevalley GF et al. [Uveitis associated with rifabutin treatment. Apropos of 3 patients]. 1995 Klin Monbl Augenheilkd pmid:7609395
Blum AL et al. [Functional dyspepsia: approaches to Helicobacter pylori eradication therapy]. 1995 Leber Magen Darm pmid:7609589
Labenz J et al. [Short-term triple therapy with pantoprazole, clarithromycin and metronidazole in eradication of Helicobacter pylori]. 1995 Leber Magen Darm pmid:7609590
Reppun JI From prontolyn to biaxin: the half-century of antibiotics. 1995 Hawaii Med J pmid:7628918
Chin DP and Hopewell PC How to treat bacteraemic Mycobacterium avium complex disease. 1995 Lancet pmid:7564723
Kuhn SM et al. Treatment of Mycobacterium marinum facial abscess using clarithromycin. 1995 Pediatr. Infect. Dis. J. pmid:7567299
Conte JE et al. Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin. 1995 Antimicrob. Agents Chemother. pmid:7726492
Saito H et al. Therapeutic effect of KRM-1648 with various antimicrobials against Mycobacterium avium complex infection in mice. 1995 Tuber. Lung Dis. pmid:7718848
Hedenmo M and Eriksson BM Liquid chromatographic determination of the macrolide antibiotics roxithromycin and clarithromycin in plasma by automated solid-phase extraction and electrochemical detection. 1995 J Chromatogr A pmid:7719451
Tseng AL and Walmsley SL Rifabutin-associated uveitis. 1995 Ann Pharmacother pmid:8573961
Moayyedi P et al. Efficacy and optimum dose of omeprazole in a new 1-week triple therapy regimen to eradicate Helicobacter pylori. 1995 Eur J Gastroenterol Hepatol pmid:8574714
Fujioka T et al. Peptic ulcer recurrence after Helicobacter pylori eradication: a 5-year follow-up study. 1995 Eur J Gastroenterol Hepatol pmid:8574733
Deltenre M et al. Omeprazole-based antimicrobial therapies: results in 198 Helicobacter pylori-positive patients. 1995 Eur J Gastroenterol Hepatol pmid:8574734
Fukuda Y et al. Combination therapy with mucosal protective agent for the eradication of Helicobacter pylori. 1995 Eur J Gastroenterol Hepatol pmid:8574735
Graham DY Clarithromycin for treatment of Helicobacter pylori infections. 1995 Eur J Gastroenterol Hepatol pmid:8574737
Takimoto T et al. Dual therapy with lansoprazole and clarithromycin for eradication of Helicobacter pylori. 1995 Eur J Gastroenterol Hepatol pmid:8574739
Uemura N et al. Effect of Helicobacter pylori eradication on the healing and recurrence of peptic ulcer: combination therapy with low-dose omeprazole and clarithromycin. 1995 Eur J Gastroenterol Hepatol pmid:8574740
Ishii K et al. In vitro dissolution tests corresponding to the in vivo dissolution of clarithromycin tablets in the stomach and intestine. 1995 Chem. Pharm. Bull. pmid:8575034
Diehl HG [One week triple therapy for eradication of Helicobacter pylori infection: simple and effective]. 1995 Leber Magen Darm pmid:8577220
Götz JM et al. Triple therapy with ranitidine, clarithromycin, and metronidazole in the treatment of Helicobacter pylori. 1995 Scand. J. Gastroenterol. Suppl. pmid:8578230
Pavlopoulou J et al. Randomized controlled study of clarithromycin versus cefaclor suspensions in the treatment of acute otitis media in children. 1995 J Chemother pmid:8904139
Stafstrom CE et al. Erythromycin-induced carbamazepine toxicity: a continuing problem. 1995 Arch Pediatr Adolesc Med pmid:7827672
Nishi K et al. [Effect of clarithromycin on symptoms and mucociliary transport in patients with sino-bronchial syndrome]. 1995 Nihon Kyobu Shikkan Gakkai Zasshi pmid:8821993
Parasakthi N and Goh KL Primary and acquired resistance to clarithromycin among Helicobacter pylori strains in Malaysia. 1995 Am. J. Gastroenterol. pmid:7872306
Kadayifçi A et al. Low dose clarithromycin plus omeprazole eradicates Helicobacter pylori in duodenal ulcer disease. 1995 Am. J. Gastroenterol. pmid:7872307
New drug applications sought. 1995 AIDS Alert pmid:11362777
Smart T Cryptosporidiosis at ICAAC. 1995 GMHC Treat Issues pmid:11362913
Researchers find new drugs to fight MAC. 1995 AIDS Alert pmid:11362925